Zydus Lifesciences Limited will buy back up to 87,30,158 fully paid-up equity shares of face value Rs 1 each, representing 0.87% of its total paid-up equity capital, at Rs 1,260 per share for an aggregate amount not exceeding Rs 1,100 crore, excluding transaction costs. The buyback will be executed through the tender offer route on a proportionate basis.
The letter of offer was submitted to BSE and NSE on May 31, 2026. The public announcement dated May 20, 2026 was published on May 21, 2026. An addendum to the public announcement dated May 27, 2026 was published on May 28, 2026. The record date for the buyback is May 29, 2026.
The buyback consideration will be paid in cash. The buyback opens on Thursday, June 4, 2026, and closes on Wednesday, June 10, 2026. Completed tender forms along with other specified documents must reach the registrar by 5:00 PM IST on June 10, 2026. Bid settlement on stock exchanges is scheduled by June 17, 2026.
The buyback size represents 5.16% of the aggregate paid-up capital and free reserves on a standalone basis and 3.84% on a consolidated basis, based on the audited financial statements as at March 31, 2026.
Small shareholders are entitled to tender 5 equity shares for every 49 shares held on the record date, translating to an entitlement of 10.195%. Shareholders in the general category can tender 7 equity shares for every 937 shares held, equivalent to 0.747%.
ICICI Securities Limited is the manager to the buyback. MUFG Intime India Private Limited is the registrar. The letter of offer is available on the websites of the company, stock exchanges and SEBI.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.